TAILORING THERAPY IN ACUTE HEART FAILURE: CAN BIOMARKERS DISTINGUISH RESPONDERS FROM NON-RESPONDERS?

Licette C.Y. Liu,Mattia A.E. Valente,Douwe Postmus,Christopher M O’Connor,Marco Metra,Piotr Ponikowski,John Teerlink,Gad Cotter,B. Davison,John G. Cleland,Michael Givertz,Daniel Bloomfield,Dirk J. van Veldhuisen,Hans L. Hillege,Peter van der Meer,Adriaan A. Voors

TAILORING THERAPY IN ACUTE HEART FAILURE: CAN BIOMARKERS DISTINGUISH RESPONDERS FROM NON-RESPONDERS?

2015

Licette C.Y. Liu
Mattia A.E. Valente
Douwe Postmus
Christopher M O’Connor
Marco Metra
Piotr Ponikowski
John Teerlink
Gad Cotter
B. Davison
John G. Cleland
Michael Givertz
Daniel Bloomfield
Dirk J. van Veldhuisen
Hans L. Hillege
Peter van der Meer
Adriaan A. Voors

Over the last 50 years, clinical trials of novel interventions for acute heart failure (AHF) have, with few exceptions, been neutral or shown harm. Biomarker profiles might identify subsets of patients that respond. We studied the effect of rolofylline on 180 day mortality across 24 clinical

Keywords:

Clinical trial
Medical emergency
Rolofylline
Internal medicine
Heart failure
Diabetes mellitus
Psychological intervention
Cardiology
Biomarker (medicine)
Medicine
Intensive care medicine
non responders

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations